The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy

Cardiovascular Research

Volumn 85, Issue 2, 2010, Pages 330-338

  Carrier, Lucie ^a,b,c   Schlossarek, Saskia ^a   Willis, Monte S ^d,e   Eschenhagen, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Sorbonne Université   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiomyopathy; Hypertrophy; Nonsense mediated mRNA decay; Ubiquitin proteasome system

Indexed keywords

MESSENGER RNA; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN; PROTEASOME; UBIQUITIN;

ENZYME ACTIVATION; GENE MUTATION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW;

ALPHA-CRYSTALLIN B CHAIN; ANIMALS; CARDIOMEGALY; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; HEART FAILURE; HUMANS; MUTATION; MYOSIN HEAVY CHAINS; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA STABILITY; UBIQUITIN;

EID: 72949085057     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp247     Document Type: Review

References (92)

1. Richardson P, McKenna W, Bristow M, Maish B, Mautner B, O'Connell J et al. Report of the 1995 World Health Organisation/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyo-pathies. Circulation 1996;93:841-842.
2. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-276.
3. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocar-diographic analysis of 4111 subjects in the CARDIA study. Circulation 1995;92: 785-789.
4. Charron P, Dubourg O, Desnos M, Bouhour JB, Isnard R, Hagège A et al. Diagnostic value of electrocardiography and echocardiography for familial hyper-trophic cardiomyopathy in genotyped children. Eur Heart J 1998;19:1377-1382.
5. Rodriguez JE, McCudden CR, Willis MS. Familial hypertrophic cardiomyopathy: basic concepts and future molecular diagnostics. Clin Biochem 2009;42:755-765.
6. Charron P, Heron D, Gargiulo M, Richard P, Dubourg O, Desnos M et al. Genetic testing and genetic counselling in hypertrophic cardiomyopathy: the French experience. J Med Genet 2002;39:741-746.
7. Soor GS, Luk A, Ahn E, Abraham JR, Woo A, Ralph-Edwards A et al. Hyper-trophic cardiomyopathy: current understanding and treatment objectives. J Clin Pathol 2009;62:226-235.
8. Teare D. Asymetrical hypertrophy of the heart in young adults. Br Heart J 1958; 20:1-8.
9. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287: 1308-1320.
10. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hyper-trophic cardiomyopathy. JAMA 2007;298:405-412.
11. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopa-thy. N Engl J Med 2000;342:1778-1785.
12. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363: 1881-1891.
13. Biagini E, Coccolo F, Ferlito M, Perugini E, Rocchi G, Bacchi-Reggiani L et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 2005;46:1543-1550.
14. Charron P, Carrier L, Dubourg O, Tesson F, Desnos M, Richard P et al. Pene-trance of familial hypertrophic cardiomyopathy. Genet Couns 1997;8:107-114.
15. Charron P, Dubourg O, Desnos M, Isnard R, Hagège A, Millaire A et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic car-diomyopathy in a genotyped adult population. Circulation 1997;96:214-219.
16. Keller DI, Carrier L, Schwartz K. Genetics of familial hypertrophic cardiomyopa-thies and arrhythmias. Swiss Med Wkly 2002;132:401-407.
17. Richard P, Villard E, Charron P, Isnard R. The genetic bases of cardiomyopathies. J Am Coll Cardiol 2006;48:A79-A89.
18. Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopa-thy: from bench to the clinics. J Cardiovasc Electrophysiol 2008;19:104-110.
19. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C et al. Hyper-trophic cardiomyopathy: distribution of disease genes, spectrum of mutations and implications for molecular diagnosis strategy. Circulation 2003;107: 2227-2232.
20. Fougerousse F, Delezoide AL, Fiszman MY, Schwartz K, Beckmann JS, Carrier L. Cardiac myosin binding protein C gene is specifically expressed in heart during murine and human development. Circ Res 1998;82:130-133.
21. Lecarpentier Y, Vignier N, Oliviero P, Guellich A, Carrier L, Coirault C. Cardiac myosin-binding protein C modulates the tuning of the molecular motor in the heart. Biophys J 2008;95:720-728.
22. Carrier L. Cardiac myosin-binding protein C in the heart. Arch Mal Coeur Vaiss 2007;100:238-243.
23. Cazorla O, Szilagyi S, Vignier N, Salazar G, Kramer E, Vassort G et al. Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice. Cardiovasc Res 2006;69:370-380.
24. Pohlmann L, Kroger I, Vignier N, Schlossarek S, Kramer E, Coirault C et al. Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. Circ Res 2007;101:928-938.
25. Colson BA, Bekyarova T, Fitzsimons DP, Irving TC, Moss RL. Radial displacement of myosin cross-bridges in mouse myocardium due to ablation of myosin binding protein-C. J Mol Biol 2007;367:36-41.
26. Charron P, Dubourg O, Desnos M, Isnard R, Hagège A, Bonne G et al. Genotype-phenotype correlations in familial hypertrophic cardiomyopathy: a comparison between mutations in the cardiac protein-C and the b-myosin heavy chain genes. Eur Heart J 1998;19:139-145.
27. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998;338:1248-1257.
28. Yu B, French JA, Carrier L, Jeremy RW, McTaggart DR, Nicholson MR et al. Molecular pathology of familial hypertrophic cardiomyopathy caused by mutations in the cardiac myosin binding protein C gene. J Med Genet 1998;35:205-210.
29. Dausse E, Komajda M, Dubourg O, Fetler L, Dufour C, Carrier L et al. Familial hypertrophic cardiomyopathy: microsatellite haplotyping and identification of a hot-spot for mutations in the b-myosin heavy chain gene. J Clin Invest 1993;92: 2807-2813.
30. Carrier L, Bonne G, Bährend E, Yu B, Richard P, Niel F et al. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hyper-trophic cardiomyopathy. Circ Res 1997;80:427-434.
31. Osterop AP, Kofflard MJ, Sandkuijl LA, ten Cate FJ, Krams R, Schalekamp MA et al. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension 1998;32:825-830.
32. Deinum J, van Gool JM, Kofflard MJ, ten Cate FJ, Danser AH. Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy. Hypertension 2001;38:1278-1281.
33. Friedrich F, Bausero P, Sun Y, Treszl A, Krämer E, Juhr D et al. A new polymorphism in human calmodulin III promoter is a potential modifier gene for familial hypertrophic cardiomyopathy. Eur Heart J 2009;30:1648-1655.
34. Cuda G, Fananapazir L, Epstein ND, Sellers JR. The in vitro motility activity of b-cardiac myosin depends on the nature of the b-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil 1997;18: 275-283.
35. Bottinelli R, Coviello DA, Redwood CS, Pellegrino MA, Maron BJ, Spirito P et al. A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res 1998;82: 106-115.
36. Keller DI, Coirault C, Rau T, Cheav T, Weyand M, Amann K et al. Human homo-zygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J Mol Cell Cardiol 2004;36:355-362.
37. Flavigny J, Souchet M, Sébillon P, Berrebi-Bertrand I, Hainque B, Mallet A et al. COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes. J Mol Biol 1999;294:443-456.
38. Rottbauer W, Gautel M, Zehelein J, Labeit S, Franz WM, Fischer C et al. Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization of cardiac transcript and protein. J Clin Invest 1997;100:475-482.
39. Moolman JA, Reith S, Uhl K, Bailey S, Gautel M, Jeschke B et al. A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation 2000;101:1396-1402.
40. van Dijk SJ, Dooijes D, Dos Remedios C, Michels M, Lamers JM, Winegrad S et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 2009;119:1473-1483.
41. Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R, Robbins J. In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy. Circ Res 1999; 85:841-847.
42. Eijssen LM, van den Bosch BJ, Vignier N, Lindsey PJ, van den Burg CM, Carrier L et al. Altered myocardial gene expression reveals possible maladaptive processes in heterozygous and homozygous cardiac myosin-binding protein C knockout mice. Genomics 2008;91:52-60.
43. Carrier L, Knoell R, Vignier N, Keller DI, Bausero P, Prudhon B et al. Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. Cardiovasc Res 2004;63: 293-304.
44. Chang YF, Imam JS, Wilkinson MF. The nonsense-mediated decay RNA surveillance pathway. Annu Rev Biochem 2007;76:51-74.
45. Maquat LE. Nonsense-mediated mRNA decay in mammals. J Cell Sci 2005;118: 1773-1776.
46. Garneau NL, Wilusz J, Wilusz CJ. The highways and byways of mRNA decay. Nat Rev Mol Cell Biol 2007;8:113-126.
47. Zhang J, Sun X, Qian Y, LaDuca JP, Maquat LE. At least one intron is required for the nonsense-mediated decay of triosephosphate isomerase mRNA: a possible link between nuclear splicing and cytoplasmic translation. Mol Cell Biol 1998;18: 5272-5283.
48. Linde L, Kerem B. Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet 2008;24:552-563.
49. Geiger SK, Bar H, Ehlermann P, Walde S, Rutschow D, Zeller R et al. Incomplete nonsense-mediated decay of mutant lamin A/C mRNA provokes dilated cardio-myopathy and ventricular tachycardia. J Mol Med 2008;86:281-289.
50. Muchir A, Massart C, van Engelen BG, Lammens M, Bonne G, Worman HJ. Proteasome-mediated degradation of integral inner nuclear membrane protein emerin in fibroblasts lacking A-type lamins. Biochem Biophys Res Commun 2006; 351:1011-1017.
51. Gong Q, Zhang L, Vincent GM, Horne BD, Zhou Z. Nonsense mutations in hERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA decay in human long-QT syndrome. Circulation 2007;116:17-24.
52. Vignier N, Schlossarek S, Fraysse B, Mearini G, Kraemer E, Pointu H et al. Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cMyBP-C mutant levels in cardiomyopathic mice. Circ Res 2009;105:239-248.
53. Zolk O, Schenke C, Sarikas A. The ubiquitin-proteasome system: focus on the heart. Cardiovasc Res 2006;70:410-421.
54. Mearini G, Schlossarek S, Willis MS, Carrier L. The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys Acta 2008;1782:749-763.
55. Ciechanover A. The ubiquitin proteolytic system: from a vague idea through basic mechanisms, and onto human diseases and drug targeting. Neurology 2006;66: S7-S19. (Pubitemid 43739979)
56. Hedhli N, Depre C. Proteasome inhibitors and cardiac cell growth. Cardiovasc Res 2010;85:321-329.
57. Sarikas A, Carrier L, Schenke C, Doll D, Flavigny J, Lindenberg KS et al. Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc Res 2005;66:33-44.
58. Mearini G, Gedicke G, Schlossarek S, Witt CC, Krämer E, Cao P et al. Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. Cardiovasc Res 2010;85:357-366.
59. Flavigny J, Robert P, Camelin J, Schwartz K, Carrier L, Berebbi-Bertrand I. Biomo-lecular interactions between human recombinant b-MyHC and cMyBP-Cs implicated in familial hypertrophic cardiomyopathy. Cardiovasc Res 2003;60:388-396.
60. Bahrudin U, Morisaki H, Morisaki T, Ninomiya H, Higaki K, Nanba E et al. Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hyper-trophic cardiomyopathy. J Mol Biol 2008;384:896-907.
61. Rappaport L, Contard F, Samuel JL, Delcayre C, Marotte F, Tome F et al. Storage of phosphorylated desmin in a familial myopathy. FEBS Lett 1988;231:421-425.
62. Vicart P, Caron A, Guicheney P, Li Z, Prevost MC, Faure A et al. A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopa-thy. Nat Genet 1998;20:92-95.
63. Wang X, Osinska H, Klevitsky R, Gerdes AM, Nieman M, Lorenz J et al. Expression of R120G-alphaB-crystallin causes aberrant desmin and alphaB-crystallin aggregation and cardiomyopathy in mice. Circ Res 2001;89:84-91.
64. Sanbe A, Osinska H, Villa C, Gulick J, Klevitsky R, Glabe CG et al. Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proc Natl Acad Sci USA 2005;102:13592-13597.
65. Chen Q, Liu JB, Horak KM, Zheng H, Kumarapeli AR, Li J et al. Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake. Circ Res 2005;97:1018-1026.
66. Liu J, Chen Q, Huang W, Horak KM, Zheng H, Mestril R et al. Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts. FASEB J 2006;20: 362-364.
67. Liu J, Tang M, Mestril R, Wang X. Aberrant protein aggregation is essential for a mutant desmin to impair the proteolytic function of the ubiquitin-proteasome system in cardiomyocytes. J Mol Cell Cardiol 2006;40:451-454.
68. Schuermann F, Schlossarek S, Mearini G, Geertz B, Vignier N, Eschenhagen T et al. Adrenergic stress unmasks exaggerated septal hypertrophy and proteasome impairment in heterozygous cMyBP-C mutant mice. (Abstract). Circulation 2008; 118:S521-S521.
69. Tsukamoto O, Minamino T, Okada K, Shintani Y, Takashima S, Kato H et al. Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochem Biophys Res Commun 2006;340: 1125-1133.
70. Razeghi P, Baskin KK, Sharma S, Young ME, Stepkowski S, Essop MF et al. Atrophy, hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin proteasome system in the rat heart. Biochem Biophys Res Commun 2006;342: 361-364.
71. Balasubramanian S, Mani S, Shiraishi H, Johnston RK, Yamane K, Willey CD et al. Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium is accompanied by changes in specific E3 ligases. J Mol Cell Cardiol 2006;41: 669-679.
72. Sultan K, Schlossarek S, Englmann D, Vignier N, Eschenhagen T, Carrier L. Alterations of the ubiquitin-proteasome system in cardiomyopathic cMyBP-C mice. (Abstract). J Mol Cell Cardiol 2007;42:S167.
73. Weekes J, Morrison K, Mullen A, Wait R, Barton P, Dunn MJ. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 2003;3:208-216.
74. Birks EJ, Latif N, Enesa K, Folkvang T, Luong le A, Sarathchandra P et al. Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res 2008;79:472-480.
75. Hedhli N, Wang L, Wang Q, Rashed E, Tian Y, Sui X et al. Proteasome activation during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22. Cardiovasc Res 2008;77:497-505.
76. Rehwinkel J, Raes J, Izaurralde E. Nonsense-mediated mRNA decay: target genes and functional diversification of effectors. Trends Biochem Sci 2006;31: 639-646.
77. Usuki F, Yamashita A, Kashima I, Higuchi I, Osame M, Ohno S. Specific inhibition of nonsense-mediated mRNA decay components, SMG-1 or Upf1, rescues the phenotype of Ullrich disease fibroblasts. Mol Ther 2006;14:351-360.
78. Kerem E. Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr Opin Pulm Med 2004;10:547-552.
79. Politano L, Nigro G, Nigro V, Piluso G, Papparella S, Paciello O et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 2003;22:15-21.
80. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999;43:1003-1012.
81. Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Pharmacogenomics 2005;6:27-36.
82. Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single-and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007;47:430-444.
83. Wood M, Yin H, McClorey G. Modulating the expression of disease genes with RNA-based therapy. PLoS Genet 2007;3:e109.
84. Meiners S, Dreger H, Fechner M, Bieler S, Rother W, Gunther C et al. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 2008;51:302-308.
85. Stansfield WE, Tang RH, Moss NC, Baldwin AS, Willis MS, Selzman CH. Protea-some inhibition promotes regression of left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 2008;294:H645-H650.
86. Hedhli N, Lizano P, Hong C, Fritzky LF, Dhar SK, Liu H et al. Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am J Physiol Heart Circ Physiol 2008;295:H1385-H1393.
87. Hacihanefioglu A, Tarkun P, Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol 2008;88:219-222.
88. Orciuolo E, Buda G, Cecconi N, Galimberti S, Versari D, Cervetti G et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haema-tol 2007;138:396-397.
89. Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer 2006;6:129.
90. Weissman AM, Yang Y, Kitagaki J, Sasiela CA, Beutler JA, O'Keefe BR. Inhibiting Hdm2 and ubiquitin-activating enzyme: targeting the ubiquitin conjugating system in cancer. Ernst Schering Found Symp Proc 2008;171-190.
91. Willis MS, Schisler JC, Portbury AL, Patterson C. Build it up-tear it down: protein quality control in the cardiac sarcomere. Cardiovasc Res 2009;81:439-448.
92. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE et al. Pro-teasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol 2003;163:1663-1675.